StevenCKatzMDFACS

General Surgery • Providence, RI

Hepatobiliary Surgery, Melanoma, Pancreas, Surgical Oncology (Other than Breast)

CMO, TriSalus Life Sciences and Surgical Oncologist at Brown Surgical Associates

Join to view full profile

Dr. Katz is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Katz's full profile

Already have an account?

Office
825 Chalkstone Avenue
Prior 4
Providence, RI 02908
Phone+1 401-456-5312

Fax+1 401-456-6708

Summary

Dr. Steven Katz is a surgical oncologist in Providence, RI and is affiliated with Women & Infants Hospital of Rhode Island and Roger Williams Medical Center. He received his medical degree from NYU School of Medicine and has been in practice 17 years. He also speaks multiple languages, including Hebrew. He specializes in hepatobiliary surgery, melanoma, and soft tissue sarcoma. He runs a translational immunotherapy program, having led five solid tumor CAR-T clinical trials and oversees cGMP cell therapy manufacturing. Dr. Katz recently joined TriSalus Life Sciences as the Chief Medical Officer and continues to practice surgical oncology in selected indications.

Education & Training

Memorial Sloan-Kettering2009
NYU Grossman School of MedicineResidency, Surgery, 2007
NYU Grossman School of MedicineInternship, Surgery, 2000 - 2001
New York University School of MedicineClass of 2000

Certifications & Licensure

RI State Medical License 2009 - 2026
NY State Medical License 2001 - 2016
OH State Medical License 2008 - 2009
American Board of Surgery Surgery

Awards, Honors, & Recognition

Fellow (FACS) American College of Surgeons

Clinical Trials

CEA-Expressing Liver Metastases Safety Study of Intrahepatic Infusions of Anti-CEA Designer T Cells Start of enrollment: 2011 Jun 01
Completed
Phase 1
CAR-T Hepatic Artery Infusions and Sir-Spheres for Liver Metastases Start of enrollment: 2015 Apr 01
Completed
Phase 1
CAR-T Hepatic Artery Infusions or Pancreatic Venous Infusions for CEA-Expressing Liver Metastases or Pancreas Cancer Start of enrollment: 2017 Feb 01
Completed
Phase 1
CAR-T Intraperitoneal Infusions for CEA-Expressing Adenocarcinoma Peritoneal Metastases or Malignant Ascites (IPC) Start of enrollment: 2018 Sep 13
Withdrawn
Phase 1
Phase 1b Study of CAR2Anti-CEA CAR-T Cell Hepatic Infusions for Pancreatic Carcinoma Patients With CEA+ Liver Metastases Start of enrollment: 2019 Jul 29
Terminated
Phase 1
Pressure Enabled Intrapancreatic Delivery of SD-101 With Checkpoint Blockade for Locally Advanced Pancreatic Adenocarcinoma Start of enrollment: 2023 Mar 01
Recruiting
Phase 1
Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver Tumors Start of enrollment: 2022 Mar 02
Active, not recruiting
Phase 1, Phase 2
Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma Start of enrollment: 2021 Aug 02
Active, not recruiting
Phase 1
Join now to see all

Publications & Presentations

PubMed

Pressure-Enabled Drug Delivery Significantly Increases Intra-Arterial Delivery of Embolic Microspheres to Liver Tumors in a Porcine Model.
David B Jaroch, Yujia Liu, Alexander Y Kim, Steven C Katz, Bryan F Cox
Journal of Vascular and Interventional Radiology. 2025-03-01
Intra-arterial Pressure-Enabled Drug Delivery Significantly Increases Penetration of Glass Microspheres in a Porcine Liver Tumor Model.
David B Jaroch, Yujia Liu, Alexander Y Kim, Steven C Katz, Bryan F Cox
Journal of Vascular and Interventional Radiology. 2024-10-01
Subcutaneous checkpoint inhibition is equivalent to systemic delivery when combined with nelitolimod delivered via pressure-enabled drug delivery for depletion of intr...
Chandra C Ghosh, Lauren Cournoyer, Yujia Liu, Alizee Ballarin, Ilan B Layman
Journal for Immunotherapy of Cancer. 2024-07-22

Journal Articles

STAT3 Inhibition Induces Bax-Dependent Apoptosis in Liver Tumor Myeloid-Derived Suppressor Cells
George Miller, N Joseph Espat, Steven C Katz, Nature

Press Mentions

TriSalus Hires Katz to Run Studies of Ex-Dynavax Cancer DrugSeptember 29th, 2020
High-Pressure Application Breakthrough Aids RWMC’s Immunotherapy AmbitionsDecember 21st, 2018
Rare Disease Day 2024: A Panel Discussion with Dr. Rahul Banerjee, Matthew Hadfield, Joseph Kalis, and Nagashree SeetharamuMarch 14th, 2024
Join now to see all

Professional Memberships

American Society of Clinical Oncology - ASCO
Member
American College of Surgeons - ACS
Member
Society of Immunotherapy for Cancer
Member
Society of Surgical Oncology - SSO
Member
Society of University Surgeons
Member
Society for Surgery of the Alimentary Tract - SSAT
Member

Other Languages

Hebrew

External Links

Roger Williams Surgical Oncology http://www.rhodeislandcancer.org
RWMC Clinical Trialshttp://www.rhodeislandcancer.org/Services/ClinicalTrials/default.aspx